

Info Sheet for Technical description

No. 0026

Organization

* Mandatoty fields

Name of Organization*	ReeNT Corporation		
Address, City, States, Zip, Country*	3-25-8, Nishi-Shinbashi, Minato-ku, Tokyo, 105-0003, JAPAN		
URL	https://reent.co.jp/		
Brief Descriptions of Organization* (Approx. 100 words)	A totally new solution for ENT diseases. Our mission is to become the leading company specialized for otorhinolaryngology with regenerative medicine and to provide new solutions for intractable diseases in ENT(Ear Nose and Throat) fields. Recently many treatments with regenerative medicine have started to come out in various fields. But as for ENT, only few and most of them at preclinical stage. Starting with cell sheets, we would like to offer a whole new treatment for patients suffering with ENT diseases all over the world.		
Contact address	Name*	Tsunetaro Morino	
	Department* / Position	CEO	
	E-mail* / TEL	morino.tsunetaro@reent.co.jp	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☒ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Tsunetaro Morino
28-Aug-25

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0026

* Mandatoty fields

Title*

**Nasal Mucosal Cell Sheet: Regenerative Medicine Product
for Difficult Middle Ear Disease**

Development Phase*

- | | | |
|---|--|--|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☒ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|--|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☒ Otolaryngology | ☐ Respiratory | ☒ Others |

Description*

The company's primary product is a regenerative medicine treatment for intractable middle ear diseases, focusing on cholesteatoma and adhesive otitis media. Cholesteatoma, if left untreated surgically, can cause severe complications like hearing loss and meningitis, and existing surgery often leads to postoperative disability due to extensive mucosal defects. For adhesive otitis media, there's currently no reliable way to prevent re-adhesion or a standardized surgical method. The company's goal is to address these unmet medical needs in otology by offering a therapeutic solution. This is achieved through a technology that cultures cell sheets from the patient's own nasal mucosa, which closely resembles the middle ear mucosa. The company also anticipates expanding this technology to other mucosal defect situations, particularly within the ENT field.

Filled in by***Date***

Yuuki Takizawa

25-Aug-04